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Introduction
The adoptive cell transfer of select tumor-infiltrating lympho-
cytes (TILs) for personalized immunotherapy can mediate 
long-term objective tumor regressions in patients with meta-
static melanoma, bile duct, cervix, colon, and breast cancers 
(1–5). These clinical responses are likely mediated by recogni-
tion of mutated gene products termed neoantigens because 
they are absent in normal tissues. Intratumoral T cell responses 
to mutated neoantigens identified thus far have been unique 
to the patient, i.e., they are private mutations not identified in 
other patients’ tumors, except for a neoepitope arising from the 
KRASG12D driver mutation (1, 3). However, it is largely unknown 
whether naturally occurring T cells within tumors recognize 
other shared mutated neoantigens expressed by cancers of 
unrelated patients.
Across all cancer types, TP53 is the most commonly mutated 
gene, but mutations occur throughout the gene with preference 
in the DNA binding domain (6, 7). Therapeutic approaches eval-
uating small-molecule inhibitors and T cells targeting both WT 
and mutant p53 tumors in mouse models have been described 
(8–11). Preliminary studies provided some evidence that mutated 
TP53 could be recognized by peripheral blood T cells after in vitro 
stimulation and in vivo vaccination (12–14). However, evidence 
of immune responses to mutated TP53 within human tumors is 
limited even though most tumors will express a TP53 mutation. 
We previously reported patient-specific neoantigen screening in 
7 patients with metastatic ovarian cancer, 2 of whom had mutated 
TP53 neoantigens restricted by HLA-DRB3*02:02 (15, 16). Here, 
we developed a novel strategy to systematically and comprehen-
sively analyze intratumoral T cell responses to defined TP53 hot 
spot mutations independent of other tumor mutations in 133 new 
patients with multiple tumor types. The goal was to translate 
these cells or their TCR genes into broadly applicable adoptive 
cellular therapies for common epithelial malignancies.
Results and Discussion
Patients with metastatic epithelial cancers were enrolled in clin-
ical trials (NCT01174121, NCT02133196, and NCT01585428) 
at the National Cancer Institute (NCI). Metastases were resected 
for growth of TILs from fragment cultures in high-dose inter-
leukin 2 (IL-2), and peripheral blood lymphocytes (PBLs) 
were collected for germline sequencing controls and to gener-
ate autologous antigen-presenting cells (APCs) for screening 
assays. A total of 140 patients diagnosed with cancers of the 
bile duct, breast, colon, cervix, endometrium, gastroesophagus, 
head and neck, lung, ovary, pancreas, and rectum were evalu-
ated. Of these patients, 91 (65%) had a tumor that expressed 
a mutation in TP53 (Figure 1A and Supplemental Table 1; 
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R248W, R249S, R273C, R273H, R273L, and R282W. A nov-
el high-throughput technique was developed using minigenes 
encoding 25 amino acid peptides containing each TP53 mutation 
and flanked by 12 amino acids of WT sequence. The peptides 
were concatenated in tandem to generate a tandem minigene 
(TMG) as has been performed in testing patient-specific neoepi-
topes (Supplemental Figure 1) (2, 3, 5). A similar TMG encoding 
the corresponding WT sequences was also generated to facil-
itate analysis of T cell specificity to the mutated variants. The 
TMGs were synthesized de novo as DNA, cloned into an expres-
sion vector plasmid DNA, and in vitro transcribed into mRNA. 
The same 25 amino acid sequences (WT or mutated) were also 
synthesized as individual peptides at greater than 95% purity 
using high-performance liquid chromatography. Immature den-
dritic cells (APCs) were generated from the autologous patients’ 
peripheral blood and were either electroporated with TMGs 
(irrelevant, WT, or mutated TP53; 12–16 minigenes each) or 
pulsed with individual WT or mutated peptides corresponding 
only to the autologous TP53 mutation. Cocultures of TIL frag-
ment cultures and prepared APCs were incubated overnight at 
37°C, and T cell responses were measured by OX40 and 41BB 
upregulation on the cell surface (flow cytometry) and secretion 
of interferon-γ (IFN-γ) using an enzyme-linked immunospot 
(ELISPOT) assay. The upregulation of 41BB was more consistent 
supplemental material available online with this article; https://
doi.org/10.1172/JCI123791DS1). A total of 93 nonsynonymous 
TP53 mutations were detected, including 14 insertions or dele-
tions (indels), 13 nonsense mutations, and 66 missense muta-
tions (Figure 1B). Tumors from 33 patients, representing 24% of 
all patients evaluated, possessed mutations within codons 175, 
220, 245, 248, 273, and 282 (Figure 1C and Supplemental Tables 
1 and 2), positions that corresponded to previously identified 
TP53 hot spots in a wide variety of cancer types (Supplemental 
Tables 3 and 4). There was no explicit bias toward a particular 
disease type in patient accrual at the NCI Surgery Branch during 
this time even though there was a preponderance of colorectal 
patients enrolled in the protocol. Studies of fresh tumor with 
available RNA-seq also demonstrated high levels of TP53 gene 
expression, regardless of TP53 mutation status (Supplemental 
Table 1). The high levels of TP53 gene expression for the target-
ed mutations, which ranged between the 89th and 100th per-
centile of all expressed transcripts, raised the possibility that 
one or more of the peptides arising from these common muta-
tions might be immunogenic in these patients.
The Catalogue of Somatic Mutations in Cancer (COSMIC) 
database (https://cancer.sanger.ac.uk/cosmic) showed that 
the 12 most common TP53 hot spot mutations across all tumor 
types were R175H, Y220C, G245S, G245D, R248L, R248Q, 
Figure 1. TP53 hot spot muta-
tions are immunogenic and elicit 
intratumoral T cell responses to 
p53 neoantigens. (A) Patients 
with a tumor expressing a TP53 
mutation. (B) Classification of 
TP53 mutations from resected 
tumors. (C) The overall frequencies 
of each missense mutation in 
TP53 from all patients sequenced 
by p53 codon where the specific 
amino acid change frequency is 
given for selected mutations. (D) 
Screening results from patient 9 
as measured by IFN-γ ELISPOT. (E) 
Expression of 41BB from patient 
9’s TIL culture 1 in response to 
TP53 TMGs. (F) Overall frequency 
of TIL responses to mutated TP53, 
which include TMG, peptide, or 
both (Supplemental Table 5). (G) 
Frequencies of verified positive TIL 
responses from selected fragment 
cultures (some patients had >1) to 
p53 R175H, Y220C, G245S, R248Q, 
R248W, and R282W neoantigens. 
The upregulation of 41BB minus 
the background in response to 
mutated p53 peptide (CD4) or TMG 
(CD8) is reported. Types of T cell 
responses can be found in Table 1.
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demonstrated this was a CD8+ T cell response (Figure 1E). Autol-
ogous PBLs and TILs were available for 28 of 33 patients (Supple-
mental Table 2). In aggregate, 39% (n = 11) of patients displayed 
a T cell response to one of the TP53 hot spot mutations under 
investigation (Figure 1F), and there was a wide range of TP53- 
reactive T cell frequencies found either through IFN-γ secretion, 
41BB upregulation, or both in response to TMG, peptide, or both 
(Figure 1G and Supplemental Table 5). T cell responses were 
readily detected against R175H, Y220C, G245S, R248Q, R248W, 
and R282W with a range of frequencies (0.1%–80% of CD3+ 
41BB+ cells) in the 11 patients with mutated TP53-reactive T cells 
(Figure 1G and Supplemental Figures 3–8). 
We next evaluated the HLA restriction elements for these 
TP53 neoantigens by transfecting DNA plasmids encoding HLA 
alleles into the COS7 cell line (15). TILs from patients 1 and 5 
recognized HLA-A*0201 neoepitopes containing p53R175H and 
p53Y220C, respectively, and TILs from patient 9 recognized an 
HLA-A*68:01– restricted neoepitope containing p53R248W (Fig-
ure 2A and Supplemental Figure 9). Of note, the only shared 
mutated TP53 neoepitope we identified was the HMTEVVRHC 
peptide, which was recognized in the context of HLA-A*02:01 
by TILs from patients 1 and 2 (Table 1). To identify HLA class 
and robust than OX40 for assessing CD4 T cell reactivities and 
was thus reported (Supplemental Figure 2). Negative controls for 
screening were dimethyl sulfoxide (DMSO; peptide vehicle) and 
T cells only (media), and a mixture of phorbol myristate acetate 
(PMA) and ionomycin as positive control. A positive response in 
the initial screening was measured if the IFN-γ secretion and/or 
41BB expression was more than twice background (Supplemen-
tal Table 5). Selected TIL fragment cultures with the most cells 
and robust responses were then rescreened in additional inde-
pendent experiments where they had to display at least 10-fold 
higher avidity to the mutated gene relative to the relevant WT 
counterpart to be considered positive.
Patient 9 exemplified the speed at which mutated TP53 
neoantigen–reactive T cells could be identified for possible 
cell-based treatment. Lung metastases were resected from this 
patient, 24 fragment cultures were grown, the screen was per-
formed, and p53R248W T cell responses were identified 34 days 
after surgery (Figure 1, D and E). Secretion of IFN-γ was off scale 
(>1000 spots) for TIL cultures 1, 3, 5, and 15 when cocultured 
with the mutated TP53 TMG (Figure 1D, red circles), and this 
was specific for the p53R248W peptide (Figure 1D, closed squares). 
Upregulation of 41BB in response to the p53R248W neoantigen 
Figure 2. Immunogenic TP53 
hot spot mutations could be 
restricted by common HLA 
alleles and targeted by TCRs 
isolated from p53 neoantigen–
reactive TILs. (A) HLA class I 
restriction of p53Y220C (patient 5, 
TIL culture 4259-F1) and p53R248W 
(patient 9, TIL culture 4266-F1) 
neoepitopes. Data are mean ± 
SEM, n = 3 technical replicates. 
> indicates 1,250 pg/ml IFN-γ. 
(B) Peptide mapping of CD4+ T 
cell responses from patient 4 
to p53R175H neoepitopes. (C) HLA 
class II restriction for p53Y220C 
neoantigen from patient 5. (D) 
HLA allele frequencies from 
selected populations (http://
www.allelefrequencies.net/
default.asp). (E) Specificity of 
HLA-DRB*13:01/p53R175H–reactive 
TCR to 25 amino acid p53R175H 
peptides.
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Beauty transposon/transposase system (18), and TCR-trans-
posed T cells were cocultured with target p53 neoepitopes. We 
previously identified p53Y220C- and p53G245S-reactive TCRs with a 
common restriction element (HLA-DRB3*02:02) from patients 
6 and 7 (15). In this study, we isolated TCRs specific for p53R175H/
HLA-A*02:01 (patient 1), p53R175H/HLA-DRB1*13:01 (patient 4), 
p53Y220C/HLA-DRB1*04:01 (patient 5), p53R248W/HLA-A*68:01 
(patient 9), and p53R248W/HLA-DPB1*02:01 (patient 10) (Figure 
2E and Supplemental Figures 9 and 11–16). A total of 9 TCRs 
recognizing 7 different p53 neoepitopes have been identified, 
which were likely unique as they were not found in the NCBI 
(https://www.ncbi.nlm.nih.gov/) and VDJDB (https://vdjdb.
cdr3.net/) databases (Supplemental Table 6). Thus, off-the-
shelf TCR gene therapy could be used for patients with tumors 
expressing the combination of one of the above HLA and p53 
neoantigen combinations.
We evaluated the ability of mutated TP53-specific T cells to 
recognize naturally processed p53 neoepitopes. An autologous 
tumor cell line generated from mouse xenografts in immuno-
compromised mice with endogenous expression of both mutat-
ed p53R248W and HLA-A*68:01 (Supplemental Figure 17) was rec-
ognized by HLA-A*68:01/p53R248W–reactive T cells from patient 
9, which was inhibited by class I–blocking antibody (Figure 3A). 
Saos2 is a TP53 knockout (p53NULL) tumor cell line commonly used 
to study TP53 biology that naturally expresses HLA-A*02:01. 
Cocultures of HLA-A*02:01/p53R175H–specific CD8+ T cells 
from patient 1 with Saos2 overexpressing p53R175H demonstrat-
ed significant specific intracellular expression of IFN-γ, tumor 
necrosis factor-α (TNF-α), and CD107a, which is indicative of 
II–restricted minimal neoepitopes within the 25 amino acid p53 
neoantigen, we tested peptides containing 15 amino acids that 
overlapped in 14 amino acids, similar to a previous study eval-
uating patient-specific neoepitopes where we identified HLA-
DRB3*02:02–restricted p53Y220C (HYNYMCNSSCMGSMN) 
and p53G245S (NTFRHSVVVPCEPPE) neoantigens from patients 
6 and 7, respectively (15). For example, TIL cultures 4285-F9 
and 4285-F6/4285-F10 from patient 4 responded to peptides 
containing the EVVRHCPH and VRHCPHHER core sequences, 
respectively (Figure 2B). Both of these p53R175H peptides were 
restricted by HLA-DRB1*13:01, and the CD4+ T cell response 
to p53R248W from patient 10 was restricted by HLA-DPB1*02:01 
(Supplemental Figures 10–12). CD4+ and CD8+ T cells elicited 
reactivity to the HLA-DRB1*04:01–restricted peptide RNT-
FRHSVVVPCE (Figure 2C) and to the HLA-A*02:01–restricted 
peptide VVPCEPPEV (Figure 2A) p53Y220C neoepitopes, respec-
tively, from patient 5. Some of the HLA alleles that presented 
the immunogenic p53 neoantigens in our patient cohort were 
frequent in Black, Asian, White, and/or Latino and Hispanic 
American populations (Figure 2D), as measured by allele fre-
quency, which is roughly half the population frequency (allele 
frequency of 0.1 corresponds to ~20% of the population), 
indicating that a diverse cohort of patients could benefit from 
mutated TP53-specific T cell immunotherapy.
A library of p53 neoantigen–specific TCRs was also gener-
ated following coculture of TILs with p53 neoantigen, sorting 
for 41BB+ cells, and single-cell reverse transcriptase PCR with 
TCR gene- specific primers (17). Peripheral blood T cells were 
genetically modified with TCRs using the nonviral Sleeping 
Figure 3. Tumor cells naturally process 
and present p53 neoantigens to T cells. 
(A) Expression of 41BB on CD8+ T cells 
expressing HLA-A*68:01/p53R248W neo-
antigen–specific TCR following coculture 
with autologous tumor cell line (TC), 
which was incubated with anti-HLA class 
I or II blocking antibodies or p53R248W 
peptide. (B) Intracellular cytokine 
staining of cocultures of CD8+ T cells 
expressing HLA-A*02:01/p53R175H neoan-
tigen–specific TCR and Saos2 cells alone 
(HLA-A*02:01+ and p53NULL; gray circles 
on left graph or gray dots on right plot) 
or overexpressing p53R175H full-length 
protein (red squares on left graph or red 
dots on right plot). (C) Secretion of IFN-γ 
in cocultures of HLA-A*02:01/p53Y220C 
neoantigen–specific T cells (CD8+-en-
riched TIL culture 4259-F1 from patient 
5) with HLA-A*02:01–positive tumors 
from unrelated donors and Saos2 tumor 
cells overexpressing full-length p53Y220C 
protein. > indicates 1,250 pg/ml IFN-γ. 
Data in panels B and C are mean ± SEM, 
n = 3 technical replicates, and 2-tailed 
Student’s t tests were performed for 
statistical analyses (**P < 0.01 and  
***P < 0.001).
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this in more detail with a larger 
patient cohort. The frequency 
of these responses was likely 
to be influenced by the HLA 
alleles expressed by patients’ 
cells. Two, three, or six patients 
had both, only CD8+, or only 
CD4+ T cell responses to 
mutated TP53, respectively 
(Table 1), suggesting that there 
are complex dynamics driving 
the immunogenicity of TP53 
hot spot mutations, which may 
include expression of HLA on 
the tumor or APC, TCR avid-
ity, and T cell trafficking to the 
tumor microenvironment.
The observation that 
11 of 28 patients (39%) rec-
ognized an autologous p53 
neoepitope suggests that 
TP53 mutations may be of value in developing cell transfer 
immunotherapy. CD4+ or CD8+ TILs selected for IFN-γ secre-
tion or 41BB upregulation in response to KRAS and passenger 
mutations have been grown to large numbers and infused into 
cancer patients, which resulted in long-term objective tumor 
regressions of breast cancer, colon cancer, and cholangiocarci-
noma (1, 2, 4), and suggests that targeting TP53 mutations could 
result in similar clinical benefit. Our focused TP53 screening 
approach could also be a model for targeting other high-value 
mutated tumor neoantigens present in large numbers of unre-
lated patients, e.g., KRAS, PIK3CA, and EGFR. Neoantigen loss 
through T cell–selective pressure in vivo could be a mechanism 
of resistance, especially when targeting tumor suppressors. 
However, the TP53 hot spot mutations may not follow this gen-
eral rule, as the WT TP53 allele is typically lost through loss of 
heterozygosity (Supplemental Table 1), and the TP53 mutation 
can inactivate WT p53 tumor suppressor function and some-
times also have gain-of-function activity, which may be critical 
for tumor survival (20). We plan to directly test the ability of T 
cells specific for TP53 mutations (TILs and TCRs) to eliminate 
metastatic cancer in clinical trials at the NCI Surgery Branch.
Methods
Antibodies used in this study can be found in Supplemental Table 8. 
Additional methods are in the Supplemental Material. 
Study approval. Written, informed consent was granted for all 
patients prior to enrollment in National Institutes of Health pro-
tocols (NCT01174121, NCT02133196, and NCT01585428), which 
were approved by the Institutional Review Board. Studies in mice 
were approved by the National Institutes of Health Institutional 
Animal Care and Use Committee.
Author contributions
PM, SAR, and DCD conceptualized and developed the project. PM, 
AP, PFR, MRP, BCP, LJ, JJG, ZY, AS, ET, VH, WL, and DCD designed 
and performed experiments and analyzed data. RPTS supervised 
T cell degranulation and tumor cytolysis, compared with cocul-
tures with parental Saos2 cells (Figure 3B). CD4+ T cells also 
degranulated in response to p53R175H, p53Y220C, and p53R248W neo-
epitopes, indicating that these cells may have the capability to 
directly lyse tumor cells (Supplemental Figures 18–20). A panel 
of HLA-A*02:01–expressing tumor cells from unrelated donors 
was cocultured with HLA-A*02:01/p53Y220C–reactive T cells 
from patient 5, which secreted significant IFN-γ in response to 
HCC2935 and U698M tumor cell lines with endogenous expres-
sion of p53Y220C and Saos2 overexpressing p53Y220C, but lacked 
IFN-γ secretion in cocultures with Saos2 (p53NULL) and SKMEL5 
(WT TP53) tumor cell lines (Figure 3C). These data indicate that 
TP53 mutational hot spot mutations can be processed and pre-
sented on the surfaces of tumor cells in the context of relevant 
HLA molecules and can be recognized by T cells.
Both CD4+ and CD8+ T cells responded to mutated TP53 neo-
antigens, and 2 of the previously reported ovarian cancer patients 
were included with the 9 new responses to accurately describe the 
totality of our experience detecting T cell responses to mutated TP53 
in 11 patients (Table 1). Our previous experience in detecting TP53 
mutation–specific T cells in ovarian cancer (15, 16) was expanded in 
this study to colorectal and pancreas cancers and 4 more TP53 hot 
spot mutations were determined to be immunogenic in the context 
of 5 new HLA restrictions. This led to an additional 7 mutated TP53- 
specific TCRs for the potential benefit of future patients with match-
ing HLA and TP53 mutations. Moreover, once it was determined 
that the tumor expressed a TP53 hot spot mutation, TIL screening 
could occur because the TMG and peptides were pre-prepared, thus 
eliminating the time and cost associated with personalized neoanti-
gen screening. It is currently unknown why T cell responses were fre-
quently observed to p53 neoepitopes, but high TP53 expression (Sup-
plemental Table 1) or increased stability of the mutant p53 protein 
could influence their immunogenicity (19). Individual codon substi-
tutions also appeared to differ in terms of the frequency with which 
they gave rise to an immunogenic epitope (Supplemental Table 7), 
although the sample size was small, and future studies can evaluate 
Table 1. Patients with T cell responses to TP53 hot spot mutations
Patient Age/Sex Cancer type Tumor no. TP53 mutation T cell type TP53 neoepitope (mutation) HLA restriction
1 52/M Colon 4141 R175H CD8 HMTEVVRHC A*02:01
2 36/F Colon 4196 R175H CD8 HMTEVVRHC A*02:01
3 55/M Colon 4252 R175H CD4 YKQSQHMTEVVRHCPHHERCSDSDG Class II
4 46/M Colon 4285 R175H CD4 VVRHCPHHERCSDSDQHMTEVVRHCPHHER DRB1*13:01
5 44/F Colon 4259 Y220C CD4CD8
RNTFRHSVVVPCE
VVPCEPPEV
DRB1*04:01
A*02:01
6 39/F Ovary 4149 Y220C CD4 NTFRHSVVVPCEPPE DRB3*02:02
7 58/F Ovary 4127 G245S CD4 HYNYMCNSSCMGSMN DRB3*02:02
8 69/F Colon 4268 R248Q CD4CD8 YMCNSSCMGGMNQRPILTIITLEDS Class I and II
9 41/F Colon 4266 R248W CD8 SSCMGGMNWR A*68:01
10 49/M Rectal 4273 R248W CD4 SCMGGMNWRPILTII DPB1*02:01
11 66/F Pancreas 4270 R282W CD4 FEVRVCACPGRDWRTEEENLRKKGE Class II
The type of T cell response, reactive p53 neoepitope (minimal when possible), and HLA restriction for each patient. 
Some T cell responses were of insufficient frequency to identify the specific HLA restriction; thus, the HLA family 
(class I or II) is denoted.
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